1 University of Colorado School of Medicine, Denver, Colorado.
2 University of Maryland School of Medicine, Baltimore, Maryland.
Ann Am Thorac Soc. 2017 Dec;14(Supplement_6):S437-S444. doi: 10.1513/AnnalsATS.201707-566OT.
Sarcoidosis is a disease with heterogeneous manifestations and outcomes, varying in part on the basis of organ involvement. Specifically, patients with sarcoidosis at risk for poor outcomes include individuals with treatment-resistant pulmonary sarcoidosis, including fibrotic pulmonary disease and pulmonary hypertension, as well as those with cardiac, neurologic, and multiorgan disease. The limited but available data relating to these patients with high-risk sarcoidosis, defined as those patients with presentations requiring medical intervention to avoid progressive disability or premature death, was evaluated as part of the National Heart, Lung, and Blood Institute's workshop to improve understanding of these disease manifestations. In particular, knowledge gaps that preclude a greater understanding of the pathogenesis and management of these severe sarcoidosis clinical phenotypes were identified in the workshop. Research strategies are proposed to address critical knowledge gaps that would further our understanding of these disease manifestations and enhance the care of these patients.
结节病是一种表现和结局具有异质性的疾病,部分取决于器官受累情况。具体而言,预后不良风险较高的结节病患者包括治疗抵抗的肺结节病患者,包括纤维化性肺疾病和肺动脉高压,以及患有心脏、神经和多器官疾病的患者。作为美国国立心肺血液研究所(National Heart, Lung, and Blood Institute)研讨会的一部分,评估了与这些高危结节病患者(定义为需要医疗干预以避免进行性残疾或过早死亡的患者)相关的有限但可用的数据,以更好地了解这些疾病表现。特别是,在研讨会上确定了导致无法更好地了解这些严重结节病临床表型的发病机制和管理的知识空白。提出了研究策略,以解决关键的知识空白,从而进一步了解这些疾病表现,并改善这些患者的护理。